Differences
This shows you the differences between two versions of the page.
Both sides previous revision Previous revision Next revision | Previous revision | ||
mrepo:topics:biologicalsamples [16/05/2018 @ 11:18] – adammoore | mrepo:topics:biologicalsamples [14/07/2023 @ 15:59] (current) – director | ||
---|---|---|---|
Line 1: | Line 1: | ||
- | [[: | ||
==== Biological Samples ===== | ==== Biological Samples ===== | ||
---- | ---- | ||
Line 17: | Line 16: | ||
Stored biological samples available from [[questionnaires: | Stored biological samples available from [[questionnaires: | ||
lithium heparin plasma, cell lines, and DNA. The following tables list the current data available from these samples.\\ \\ | lithium heparin plasma, cell lines, and DNA. The following tables list the current data available from these samples.\\ \\ | ||
- | {{mrepo:bloods_1999.jpg? | + | < |
+ | <table x:str="" | ||
+ | < | ||
+ | <tr style=" | ||
+ | <td class=" | ||
+ | < | ||
+ | </ | ||
+ | <td class=" | ||
+ | < | ||
+ | </ | ||
+ | <td class=" | ||
+ | < | ||
+ | </ | ||
+ | <td class=" | ||
+ | < | ||
+ | </ | ||
+ | <td class=" | ||
+ | < | ||
+ | </ | ||
+ | </ | ||
+ | < | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | < | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | </ | ||
+ | |||
+ | < | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>1 x 3ml EDTA tube</ | ||
+ | </ | ||
+ | < | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | </ | ||
+ | |||
+ | < | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>1 x 2ml EDTA tube</ | ||
+ | </ | ||
+ | < | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | </ | ||
+ | |||
+ | < | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>1 x 6ml ACD tube</ | ||
+ | </ | ||
+ | < | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p> ECACC </ | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | </ | ||
+ | |||
+ | <tr > | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>1 x 4ml Lithium heparin tube</ | ||
+ | </ | ||
+ | < | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | </ | ||
+ | |||
+ | <tr > | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>1 x 3ml EDTA tube</ | ||
+ | </ | ||
+ | < | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | </ | ||
+ | </ | ||
+ | </ | ||
+ | </ | ||
+ | |||
+ | |||
+ | |||
+ | |||
---- | ---- | ||
\\ | \\ | ||
Line 28: | Line 161: | ||
DNA extractions were conducted on the EDTA tube used in the first round blood haematology analysis. Samples for lymphoid cell line transformations were originally collected in 1999; for those that did not previously provide a sample, one was collected in 2006-10. \\ \\ | DNA extractions were conducted on the EDTA tube used in the first round blood haematology analysis. Samples for lymphoid cell line transformations were originally collected in 1999; for those that did not previously provide a sample, one was collected in 2006-10. \\ \\ | ||
- | {{mrepo:bloods_0610.jpg? | + | |
+ | < | ||
+ | <table x:str="" | ||
+ | < | ||
+ | <tr style=" | ||
+ | <td class=" | ||
+ | < | ||
+ | </ | ||
+ | <td class=" | ||
+ | < | ||
+ | </ | ||
+ | <td class=" | ||
+ | < | ||
+ | </ | ||
+ | <td class=" | ||
+ | < | ||
+ | </ | ||
+ | </ | ||
+ | < | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>1 x 2.7ml EDTA tube (EN1)</ | ||
+ | </ | ||
+ | < | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | </ | ||
+ | |||
+ | < | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>1 x 2.7ml EDTA tube (EN2)</ | ||
+ | </ | ||
+ | < | ||
+ | <p> None as sample was sent for HbA1c and red cell folate analysis <p> | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | </ | ||
+ | |||
+ | < | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>1 x 2.7ml Fluoride tube (FL N1)</ | ||
+ | </ | ||
+ | < | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | </ | ||
+ | |||
+ | < | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>1 x 7.5ml Lithium heparin tube (trace metal) (LH N1)</ | ||
+ | </ | ||
+ | < | ||
+ | <p>LH INS for insulin; LH VITC for vitamin C analysis</ | ||
+ | </ | ||
+ | <td > | ||
+ | <p>LH B1, LH C1, LH C2, LH C3 </ | ||
+ | </ | ||
+ | </ | ||
+ | |||
+ | <tr > | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>1 x 8.5ml CPDA (for cell lines if required) (CP N1)</ | ||
+ | </ | ||
+ | < | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | </ | ||
+ | |||
+ | <tr > | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>1 x 7.5ml Serum tube (SE N1)</ | ||
+ | </ | ||
+ | < | ||
+ | <p> Samples from the two serum tubes were used to produce priority aliquots SE A1 for TFTs and SE A2 for analyses at NHR</ | ||
+ | </ | ||
+ | <td > | ||
+ | <p>SE B1, SE C1, SE C2</ | ||
+ | </ | ||
+ | </ | ||
+ | |||
+ | <tr > | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>1 x 7.5ml Serum tube (SE N2)</ | ||
+ | </ | ||
+ | < | ||
+ | <p> Samples from the two serum tubes were used to produce priority aliquots SE A1 for TFTs and SE A2 for analyses at NHR</ | ||
+ | </ | ||
+ | <td > | ||
+ | <p>SE B1, SE C1, SE C2</ | ||
+ | </ | ||
+ | </ | ||
+ | |||
+ | <tr > | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>1 x 4.9ml EDTA tube (E N3)</ | ||
+ | </ | ||
+ | < | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>E B1, E C1</ | ||
+ | </ | ||
+ | </ | ||
+ | <tr > | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>1 x 10ml Citrate tube (CI N1)</ | ||
+ | </ | ||
+ | < | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>CI B1, CI C1, CI C2</ | ||
+ | </ | ||
+ | </ | ||
+ | |||
+ | </ | ||
+ | </ | ||
+ | </ | ||
+ | *Blood tubes/ | ||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
\\ \\ | \\ \\ | ||
__Urine__ | __Urine__ | ||
Line 46: | Line 340: | ||
A number of assays have been undertaken and the remaining aliquots of EDTA, citrate plasma and serum are stored at the Bristol Bioresource Laboratories. | A number of assays have been undertaken and the remaining aliquots of EDTA, citrate plasma and serum are stored at the Bristol Bioresource Laboratories. | ||
- | {{mrepo:bloods_14.jpg? | + | < |
+ | <table x:str="" | ||
+ | < | ||
+ | <tr style=" | ||
+ | <td class=" | ||
+ | < | ||
+ | </ | ||
+ | <td class=" | ||
+ | < | ||
+ | </ | ||
+ | <td class=" | ||
+ | < | ||
+ | </ | ||
+ | <td class=" | ||
+ | < | ||
+ | </ | ||
+ | </ | ||
+ | < | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>1 x 2.7ml citrate</ | ||
+ | </ | ||
+ | < | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td > | ||
+ | < | ||
+ | </td> | ||
+ | <td > | ||
+ | <p>1 x 5ml Serum</ | ||
+ | </td> | ||
+ | <td> | ||
+ | <p> Cholesterol, | ||
+ | </td> | ||
+ | <td > | ||
+ | < | ||
+ | </td> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td > | ||
+ | < | ||
+ | </td> | ||
+ | <td > | ||
+ | <p>1 x 5ml Serum</ | ||
+ | </td> | ||
+ | <td> | ||
+ | < | ||
+ | </td> | ||
+ | <td > | ||
+ | < | ||
+ | </td> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td > | ||
+ | < | ||
+ | </td> | ||
+ | <td > | ||
+ | <p>1 x 5ml Serum</ | ||
+ | </td> | ||
+ | <td> | ||
+ | < | ||
+ | </td> | ||
+ | <td > | ||
+ | < | ||
+ | </td> | ||
+ | </tr> | ||
+ | <tr > | ||
+ | <td > | ||
+ | < | ||
+ | </td> | ||
+ | <td > | ||
+ | <p>1 x 4ml EDTA</ | ||
+ | </td> | ||
+ | <td> | ||
+ | < | ||
+ | </td> | ||
+ | <td > | ||
+ | < | ||
+ | </td> | ||
+ | </tr> | ||
+ | <tr > | ||
+ | <td > | ||
+ | < | ||
+ | </td> | ||
+ | <td > | ||
+ | <p>1 x 4ml EDTA </p> | ||
+ | </td> | ||
+ | <td> | ||
+ | <p> None</ | ||
+ | </td> | ||
+ | <td > | ||
+ | < | ||
+ | </td> | ||
+ | </tr> | ||
+ | </ | ||
+ | </ | ||
+ | </ | ||
+ | ---- | ||
+ | \\ | ||
+ | ^ | ||
- | ^ Table 2 - Biomarkers available at age 53 and 63. Biomarkers highlighted in bold are not present in other UK birth cohorts | + | ^System |
- | ^System | + | |**Metabolic** |
- | |**Metabolic** | + | | ::: |
- | | ::: | + | | ::: |
- | | ::: | + | | ::: |Cholesterol, |
- | | ::: |Triglycerides | + | | ::: |Triglycerides |
- | | ::: |Glycated Haemoglobin, | + | | ::: |
- | | ::: | + | |
| ::: | | ::: | ||
| ::: | | ::: | ||
| ::: | | ::: | ||
| ::: | | ::: | ||
- | | ::: | + | | ::: |Glycated Haemoglobin, |
|**Diet & Iron Markers**| | |**Diet & Iron Markers**| | ||
- | | ::: | + | | ::: |
| ::: | | ::: | ||
| ::: | | ::: | ||
| ::: | | ::: | ||
|**Inflammatory** | |**Inflammatory** | ||
- | | ::: | + | | ::: |
| ::: | | ::: | ||
- | | ::: | + | | ::: |
- | | ::: | + | | ::: |
| ::: | | ::: | ||
| ::: | | ::: | ||
Line 88: | Line 487: | ||
| ::: | | ::: | ||
| ::: | | ::: | ||
- | | ::: | + | | ::: |
| ::: | | ::: | ||
| ::: | | ::: | ||
| ::: | | ::: | ||
- | | ::: | + | | ::: |
- | | ::: | + | | ::: |
- | | ::: | + | | ::: |
| ::: | | ::: | ||
| ::: | | ::: | ||
| ::: | | ::: | ||
- | | ::: | + | | ::: |
- | | ::: | + | | ::: |
- | |**Neuro-Endocrine** | + | |**Neuro-Endocrine** |
- | | ::: |Insulin Growth Factor 1, IGF-1 (nmol/L) |DHEAS (umol/ | + | | ::: |DHEAS (umol/L) |DHEAS (umol/ |
- | | ::: |Sex hormone binding globulin, SHBG (nmol/ | + | | ::: |Insulin Growth Factor 1, IGF-1 (nmol/ |
- | | ::: |Testosterone (nmol/ | + | | ::: |
| ::: | | ::: | ||
- | | ::: | + | | ::: |Sex hormone binding globulin, SHBG (nmol/ |
- | | ::: | + | | ::: |Testosterone (nmol/ |
| ::: | | ::: | ||
| ::: | | ::: | ||
Line 134: | Line 533: | ||
- | |||
- | ---- | ||
- | |||
- | === DNA === | ||
- | |||
- | Around 2,900 study members have given consent for DNA to be extracted | ||
- | from blood and / or buccal samples and LHA was given ethical approval in | ||
- | 2007 to use these samples for genetic studies of lifelong health and | ||
- | ageing. \\ | ||
- | Genetic studies help us to elucidate biological mechanisms of | ||
- | ageing and understand why people with similar life experiences age | ||
- | differently. | ||
- | |||
- | The NSHD DNA Repository supports high calibre studies of human health | ||
- | and disease that make the best use of the genetic resource in | ||
- | conjunction with the existing life course data. Dr Andrew Wong | ||
- | coordinates the genetic research of the NSHD and is responsible for | ||
- | the safe storage and efficient use of the samples, which are managed | ||
- | by Source BioScience. | ||
- | |||
- | {{mrepo: | ||
- | available. | ||